The association between psoriasis and dyslipidaemia: A systematic review

British Journal of Dermatology

Volumn 168, Issue 3, 2013, Pages 486-495

  Ma, C ^a   Harskamp, C T ^a   Armstrong, E J ^b   Armstrong, A W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DYSLIPIDEMIA; EPIDEMIOLOGY; HUMAN; PSORIASIS; REVIEW;

DYSLIPIDEMIAS; EPIDEMIOLOGIC METHODS; HUMANS; PSORIASIS;

EID: 84882248311     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12101     Document Type: Review

References (58)

1. Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. J Am Acad Dermatol 2009;60:218-24.
2. Liu Y, Krueger JG, Bowcock AM. Psoriasis: genetic associations and immune system changes. Genes Immun 2007;8:1-12.
3. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009;361:496-509.
4. Armstrong AW, Voyles SV, Armstrong EJ et al. A tale of two plaques: convergent mechanisms of T-cell-mediated inflammation in psoriasis and atherosclerosis. Exp Dermatol 2011;20:544-9.
5. Armstrong AW, Voyles SV, Armstrong EJ et al. Angiogenesis and oxidative stress: common mechanisms linking psoriasis with atherosclerosis. J Dermatol Sci 2011;63:1-9.
6. Miller M, Seidler A, Moalemi A, Pearson TA. Normal triglyceride levels and coronary artery disease events: the Baltimore Coronary Observational Long-Term Study. J Am Coll Cardiol 1998;31:1252-7.
7. Genest JJ Jr, Martin-Munley SS, McNamara JR et al. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 1992;85:2025-33.
8. Wilson PW. Established risk factors and coronary artery disease: the Framingham Study. Am J Hypertens 1994;7:7S-12S.
9. Manninen V, Tenkanen L, Koskinen P et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992;85:37-45.
10. Warnecke C, Manousaridis I, Herr R et al. Cardiovascular and metabolic risk profile in German patients with moderate and severe psoriasis: a case control study. Eur J Dermatol 2011;21:761-70.
11. Al-Mutairi N, Al-Farag S, Al-Mutairi A, Al-Shiltawy M. Comorbidities associated with psoriasis: an experience from the Middle East. J Dermatol 2010;37:146-55.
12. Schmitt J, Ford DE. Psoriasis is independently associated with psychiatric morbidity and adverse cardiovascular risk factors, but not with cardiovascular events in a population-based sample. J Eur Acad Dermatol Venereol 2010;24:885-92.
13. Dreiher J, Weitzman D, Davidovici B et al. Psoriasis and dyslipidaemia: a population-based study. Acta Derm Venereol 2008;88:561-5.
14. Mallbris L, Granath F, Hamsten A, Ståhle M. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol 2006;54:614-21.
15. Neimann AL, Shin DB, Wang X et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006;55:829-35.
16. Armstrong AW, Lin SW, Chambers CJ et al. Psoriasis and hypertension severity: results from a case-control study. PLoS ONE 2011;6:e18227.
17. Augustin M, Reich K, Glaeske G et al. Co-morbidity and age-related prevalence of psoriasis: analysis of health insurance data in Germany. Acta Derm Venereol 2010;90:147-51.
18. Chen YJ, Shen JL, Wu CY et al. Elevated plasma osteopontin level is associated with occurrence of psoriasis and is an unfavorable cardiovascular risk factor in patients with psoriasis. J Am Acad Dermatol 2009;60:225-30.
19. Chen YJ, Wu CY, Shen JL et al. Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome. Arch Dermatol 2008;144:1571-5.
20. Cohen AD, Gilutz H, Henkin Y et al. Psoriasis and the metabolic syndrome. Acta Derm Venereol 2007;87:506-9.
21. Cohen AD, Sherf M, Vidavsky L et al. Association between psoriasis and the metabolic syndrome. A cross-sectional study. Dermatology 2008;216:152-5.
22. Driessen RJ, Boezeman JB, Van De Kerkhof PC, De Jong EM. Cardiovascular risk factors in high-need psoriasis patients and its implications for biological therapies. J Dermatolog Treat 2009;20:42-7.
23. Gerdes S, Zahl VA, Knopf H et al. Comedication related to comorbidities: a study in 1203 hospitalized patients with severe psoriasis. Br J Dermatol 2008;159:1116-23.
24. Kaye JA, Li L, Jick SS. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol 2008;159:895-902.
25. Langan SM, Seminara NM, Shin DB et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol 2012;132:556-62.
26. Love TJ, Qureshi AA, Karlson EW et al. Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003-2006. Arch Dermatol 2011;147:419-24.
27. Nisa N, Qazi MA. Prevalence of metabolic syndrome in patients with psoriasis. Indian J Dermatol Venereol Leprol 2010;76:662-5.
28. Shapiro J, Cohen AD, Weitzman D et al. Psoriasis and cardiovascular risk factors: a case-control study on inpatients comparing psoriasis to dermatitis. J Am Acad Dermatol 2012;66:252-8.
29. Sommer DM, Jenisch S, Suchan M et al. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006;298:321-8.
30. Takahashi H, Takahashi I, Honma M et al. Prevalence of metabolic syndrome in Japanese psoriasis patients. J Dermatol Sci 2010;57:143-4.
31. Wakkee M, Meijer W, Neumann HA et al. Psoriasis may not be an independent predictor for the use of cardiovascular and anti-diabetic drugs: a 5-year prevalence study. Acta Derm Venereol 2009;89:476-83.
32. Wolkenstein P, Revuz J, Roujeau JC et al. Psoriasis in France and associated risk factors: results of a case-control study based on a large community survey. Dermatology 2009;218:103-9.
33. Wu Y, Mills D, Bala M. Psoriasis: cardiovascular risk factors and other disease comorbidities. J Drugs Dermatol 2008;7:373-7.
34. Xiao J, Chen LH, Tu YT et al. Prevalence of myocardial infarction in patients with psoriasis in central China. J Eur Acad Dermatol Venereol 2009;23:1311-5.
35. Micha R, Wallace SK, Mozaffarian D. Red and processed meat consumption and risk of incident coronary heart disease, stroke, and diabetes mellitus: a systematic review and meta-analysis. Circulation 2010;121:2271-83.
36. Siasos G, Tousoulis D, Oikonomou E et al. Inflammatory markers in hyperlipidemia: from experimental models to clinical practice. Curr Pharm Des 2011;17:4132-46.
37. Libby P. Inflammation in atherosclerosis. Nature 2002;420:868-74.
38. Ribatti D, Levi-Schaffer F, Kovanen PT. Inflammatory angiogenesis in atherogenesis - a double-edged sword. Ann Med 2008;40:606-21.
39. Mizutani H, Ohmoto Y, Mizutani T et al. Role of increased production of monocytes TNF-alpha, IL-1beta and IL-6 in psoriasis: relation to focal infection, disease activity and responses to treatments. J Dermatol Sci 1997;14:145-53.
40. Arican O, Aral M, Sasmaz S et al. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm 2005;2005:273-9.
41. Feingold KR, Marshall M, Gulli R et al. Effect of endotoxin and cytokines on lipoprotein lipase activity in mice. Arterioscler Thromb 1994;14:1866-72.
42. Greenberg AS, Nordan RP, McIntosh J et al. Interleukin 6 reduces lipoprotein lipase activity in adipose tissue of mice in vivo and in 3T3-L1 adipocytes: a possible role for interleukin 6 in cancer cachexia. Cancer Res 1992;52:4113-6.
43. Beutler BA, Cerami A. Recombinant interleukin 1 suppresses lipoprotein lipase activity in 3T3-L1 cells. J Immunol 1985;135:3969-71.
44. Feingold KR, Grunfeld C. Role of cytokines in inducing hyperlipidemia. Diabetes 1992;41(Suppl. 2):97-101.
45. Memon RA, Grunfeld C, Moser AH, Feingold KR. Tumor necrosis factor mediates the effects of endotoxin on cholesterol and triglyceride metabolism in mice. Endocrinology 1993;132:2246-53.
46. Feingold KR, Serio MK, Adi S et al. Tumor necrosis factor stimulates hepatic lipid synthesis and secretion. Endocrinology 1989;124:2336-42.
47. Endres M. Statins: potential new indications in inflammatory conditions. Atheroscler Suppl 2006;7:31-5.
48. Menge T, Hartung HP, Stüve O. Statins - a cure-all for the brain? Nat Rev Neurosci 2005;6:325-31.
49. Faghihi T, Radfar M, Mehrabian Z et al. Atorvastatin for the treatment of plaque-type psoriasis. Pharmacotherapy 2011;31:1045-50.
50. Vasiuk I, Perlamutrov I, Shkol'nik MN, Shkol'nik EL. [Possibilities of atorvastatin in complex management of extensive psoriasis in patients with arterial hypertension.] Kardiologiia 2010;50:37-46 (in Russian).
51. Naseri M, Hadipour A, Sepaskhah M, Namazi MR. The remarkable beneficial effect of adding oral simvastatin to topical betamethasone for treatment of psoriasis: a double-blind, randomized, placebocontrolled study. Niger J Med 2010;19:58-61.
52. Brauchli YB, Jick SS, Meier CR. Statin use and risk of first-time psoriasis diagnosis. J Am Acad Dermatol 2011;65:77-83.
53. Shirinsky IV, Shirinsky VS. Efficacy of simvastatin in plaque psoriasis: a pilot study. J Am Acad Dermatol 2007;57:529-31.
54. Vis M, Nurmohamed MT, Wolbink G et al. Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. J Rheumatol 2005;32:252-5.
55. Kiortsis DN, Mavridis AK, Filippatos TD et al. Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol 2006;33:921-3.
56. Tam LS, Tomlinson B, Chu TT et al. Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clin Rheumatol 2007;26:1495-8.
57. Mathieu S, Dubost JJ, Tournadre A et al. Effects of 14 weeks of TNF alpha blockade treatment on lipid profile in ankylosing spondylitis. Joint Bone Spine 2010;77:50-2.
58. Lestre S, Diamantino F, Veloso L et al. Effects of etanercept treatment on lipid profile in patients with moderate-to-severe chronic plaque psoriasis: a retrospective cohort study. Eur J Dermatol 2011;21:916-20.